Jazz

Neurology Oncology Radiology

Annual license for jazz software.
Regulatory Status Disclosed

Overview

Jazz by AI Medical AG is an AI-powered software solution designed for neuroradiological image analysis. It specializes in the efficient assessment of magnetic resonance (MR) follow-up scans, particularly for conditions such as multiple sclerosis and brain metastasis. The software features an interactive user interface and integrates AI-based capabilities to deliver precise lesion detection and description, significantly reducing radiologists’ reading time.

Jazz automates repetitive, low-level tasks, enhancing productivity and the quality of neuroradiological reporting. It provides standardized digitalization of findings within the patient’s anatomical space with quantitative precision. The tool can volumetrically quantify and track lesions over extended periods, offering valuable data on statistical lesion evolution. It automatically counts and measures lesions, generating comprehensive documentation in formats like CSV, DICOM, PDF, and RTF.

By streamlining the analysis of MRI images, Jazz supports the quantitative monitoring of brain diseases, allowing radiologists and radio-oncologists to produce high-quality reports faster and with greater accuracy. It seamlessly integrates into existing clinical workflows, including PACS, RIS, and CIS.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Precise lesion detection and description
  • AI-based features for automated image analysis
  • Volumetric quantification and long-term tracking of lesions
  • Standardized digitalization of radiological findings
  • Automated lesion annotations, volume measurements, and counts
  • Generation of comprehensive radiological reports
  • Seamless integration with clinical workflows (PACS, RIS, CIS)
  • Interactive user interface
  • Supports multiple sclerosis and metastasis follow-up assessments
  • Time-saving and improved diagnostic accuracy

Use Cases

  • Assessment of magnetic resonance follow-up scans
  • Multiple sclerosis follow-up assessments
  • Brain metastasis follow-up assessments
  • Quantitative monitoring of brain diseases
  • Producing high-quality radiology reports faster and with higher accuracy
  • Digitalization of radiological findings

Details

Category Neurology AI, Oncology AI, Radiology & Imaging AI
Pricing Annual license for jazz software.
Mobile AppJazz eCare (for Jazz mobile customers, not directly related to AI Medical's Jazz software or Jazz Pharmaceuticals). MedIQ (Pakistan's first digitally integrated hybrid healthcare platform) is available via mobile applications. BIMA Mobile App offers teleconsultations for Jazz customers.
Data ExportUnknown
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Neurology, Oncology, Radiology

What the Web Says

Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for patients with rare diseases, including therapies for epilepsies, cancers, and sleep disorders. The company emphasizes a patient-focused and science-driven approach to research and development. While some employees praise the company culture, pay, and benefits, there are also concerns raised by patients and former employees regarding product pricing, customer service, and internal organizational challenges.

Overall: Mixed

Strengths

  • Commitment to innovation in the pharmaceutical industry.
  • Patient-focused and science-driven approach to research and development.
  • Competitive pay and good benefits for employees.
  • Positive and collaborative work environment with supportive management in some areas.
  • Ability to meet personal goals and time/location flexibility for employees.
  • Strong oncology franchise and pipeline with potential for growth.

Limitations

  • High pricing of medications, making them inaccessible for some patients.
  • Issues with customer service and prescription refills, leading to delays and stress for patients.
  • Concerns about the company's primary goal being sales over patient safety.
  • Understaffed teams and organizational changes causing uncertainty among employees.
  • Perceived lack of accountability at the executive level and politics over performance.
  • Side effects of medications like Xywav, including erratic heart rate and severe cataplexy, which some claim are not adequately acknowledged by company nurses.

Based on reviews from: tandfonline.com, gotoper.com, fiercebiotech.com, jazzpharma.com, indeed.com, trustradius.com, capterra.com, quora.com, reddit.com, comparably.com, fool.com, public.com, americanpharmaceuticalreview.com, liangyihui.net, fiercepharma.com

Last updated: 2026-10-28

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Jazz

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

jazzpharma.com
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
Jazz Pharmaceuticals announced updated overall survival results from the Phase 3 HERIZON-GEA-01 trial for Ziihera in HER2-positive advanced gastroesophageal adenocarcinoma, presented at ESMO 2026. The results showed sustained survival benefits with Ziihera combinations.
2026-10
jazzpharma.com
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
Jazz Pharmaceuticals announced it will report its third-quarter 2026 financial results on November 2, 2026. This announcement provides investors with the date for their upcoming financial update.
2026-10
jazzpharma.com
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
Jazz Pharmaceuticals successfully completed its acquisition of Actio Biosciences, adding ABS-1230, a clinical-stage therapy for KCNT1-related epilepsy, to its pipeline. This acquisition strengthens Jazz's commitment to advancing treatment options for rare diseases.
2026-09
jazzpharma.com
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
The FDA approved two Ziihera-containing regimens for the first-line treatment of adults with HER2-positive advanced gastroesophageal adenocarcinoma. This approval is based on results from the Phase 3 HERIZON-GEA-01 trial.
2026-08
jazzpharma.com
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
Jazz Pharmaceuticals announced a definitive agreement to acquire Actio Biosciences for $820 million upfront, with potential for an additional $500 million in contingent payments. This acquisition aims to expand Jazz's rare epilepsy portfolio with Actio's lead clinical asset, ABS-1230.
2026-08
jazzpharma.com
Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
Jazz Pharmaceuticals reported strong second-quarter 2026 financial results, with a 16% year-over-year total revenue growth and an increase in their full-year revenue guidance. The company highlighted strong commercial execution across its business.
2026-08
prnewswire.com
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
The New England Journal of Medicine published results from the Phase 3 HERIZON-GEA-01 trial, demonstrating durable and consistent survival benefits with Ziihera combinations in HER2-positive gastroesophageal adenocarcinoma. This publication supports the efficacy of these treatment regimens.
2026-05
prnewswire.com
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
Jazz Pharmaceuticals announced its financial results for the first quarter of 2026. The report provides an overview of the company's financial performance during that period.
2026-05

Videos

Product demos, reviews, and walkthroughs for Jazz.

View all on YouTube

Frequently Asked Questions

Jazz Pharmaceuticals is expanding its use of AI, particularly in its neuroscience franchise, which includes treatments for sleep disorders and epilepsy. They are leveraging machine learning to improve clinical trial design, reproducibility, and regulatory readiness in neuroscience.
Jazz Pharmaceuticals is committed to ethical behavior and compliance with all applicable laws, rules, regulations, and corporate policies, including those related to AI. They have a Global Ethics and Compliance Program and encourage reporting of potential violations.
While AI offers significant opportunities in neuropharmacology, potential limitations include data bias, challenges in model interpretability, an incomplete understanding of brain biology, and translational bottlenecks. These factors can limit the clinical success of AI-driven strategies.
Other companies are also utilizing AI in drug discovery and development for neurological conditions. For instance, companies like IBM are developing AI to drive discovery in the industry, and researchers are using AI to repurpose existing drugs for neurodegenerative diseases.
Jazz Pharmaceuticals provides a Medical Affairs Portal and a medical information department for healthcare professionals to request specific product information. While they are expanding their use of AI internally for research and development, their publicly available AI tools are primarily for internal use or for directing users to scientific materials, with a disclaimer that the AI model is learning and should not replace professional judgment.

Related Tools

Parkiwatch
Koios Care
Neurology AI
Parkiwatch by Koios Care is a Class IIa Software as a Medical Device (EU MDR 2017/745) for continuous, passive detection and quantitative assessment of kinematic patterns representative of tremor, bradykinesia, and dyskinesia in adults with Parkinson's Disease.
CortiCare (Virtual EEG Department)
CortiCare
Neurology AI
CortiCare offers 24/7 remote EEG monitoring and interpretation services, functioning as a virtual EEG department to assist hospitals and neurology practices in identifying seizures and other neurological conditions.
NeuroAstra
Avinya NeuroTech
Clinical Decision Support & Reference
NeuroAstra is an AI-enabled EEG analysis and reporting software that provides a multimodal clinical EEG web platform with Co-Pilot AI to help neuro care teams detect abnormal trends faster and standardize reporting.
Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
MeRT System
Wave Neuroscience
Mental & Behavioral Health AI
MeRT (Magnetic e-Resonance Therapy) is an advanced, personalized form of TMS that uses your own brainwave data to guide treatment. It's a non-invasive, drug-free option designed to help the brain communicate more efficiently so symptoms of conditions like depression, anxiety, PTSD, TBI, autism, and more can improve.

See all Neurology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.